Lars Fruergaard Jørgensen is a CEO who didn't want to be CEO but under his tenure Novo Nordisk, which makes Ozempic, has ...

Lexaria executing a triple-pronged strategy in obesity and diabetesSemaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience ...

After quite a crushing bull stampede in 2024, the stock price of weight loss drug star Novo Nordisk (NYSE: NVO) has come down ...

Novo Nordisk A/S, Apollo Global Management, BlackRock, Blackstone, Prologis, Welltower, and Ventas are the seven Growth ...

AstraZeneca has opened a plant to produce biogas from organic waste that will ensure by the end of this year all of its ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...

Locality Bank officially completed its de novo period on January 12, 2025, marking a significant milestone and the end of the initial three-year supervisory phase for newly chartered banks, ...

Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...

Here are five things to know about the company's de novo strategy: 1. USPI added nearly 70 ASCs in 2024, remaining "very active in both [mergers and acquisitions] and de novo development." The company ...

Today we'll look at six European stocks that could continue outperforming in 2025. Some of these companies are available to ...